Stingray Therapeutics INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersHouston, TX
US patents5
SAM.gov UEIXNADTMZYJMP5
CAGE code826P1
Incorporated inDE
- ENPP1 inhibitor
- cancer immunotherapy
- clinical trials
- multiple indications
- funding
- CPRIT
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
5 US patents granted 2020–2024, 4 of them in the five years to SEP 2025.
Organic fine chemistry 4Pharmaceuticals 1
- Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereofUS 12,152,015 · granted NOV 26, 2024
- Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereofUS 11,591,313 · granted FEB 28, 2023
- Quinoline and quinazoline compounds and methods of use thereofUS 11,407,729 · granted AUG 9, 2022
- Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeuticsUS 11,142,524 · granted OCT 12, 2021
- Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeuticsUS 10,689,376 · granted JUN 23, 2020
Granted to Stingray Therapeutics, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Stingray Therapeutics INC | Houston | TX | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.